Evotec shares rise after second IND acceptance with Bristol Myers

STREETINSIDER.COMNov 19, 12:22 PM UTC

Key insights

  • Evotec SE shares rose after its protein degradation partnership with Bristol Myers Squibb received a second Investigational New Drug (IND) acceptance from the FDA. The second drug candidate, a cereblon E3 ligase modulator, will enter Phase 1 trials in 2027. This development highlights progress in their collaboration focused on molecular glue degraders, leveraging Evotec's platforms and Bristol Myers Squibb's CELMoD agent library.
Evotec shares rise after second IND acceptance with Bristol Myers

Investing.com -- Evotec SE shares climbed 2% on Thursday after the company said that its protein degradation partnership with Bristol Myers Squibb received a second Investigational New Drug acceptance from the U.S. Food and Drug Administration.

The second drug candidate, a cereblon E3 ligase modulator, is set to begin a Phase 1 clinical trial in 2027.

The partnership’s first candidate started a Phase 1 clinical trial for advanced clear cell renal cell carcinoma in March 2026. The collaboration, which began in 2018 and was expanded in 2022, brings together Evotec’s multi-omics screening, AI-supported data analytics, and drug design capabilities with Bristol Myers Squibb’s CELMoD agent library.

Molecular glue degraders are compounds that create interactions between an E3 ubiquitin ligase and a molecular target, leading to degradation of the recruited protein.

CELMoDs create interactions between CRBN and substrate proteins, allowing for pharmacological modulation of proteins that may not respond to traditional inhibitor or agonist approaches.

The partnership focuses on discovering and developing molecular glue degraders for therapeutic uses through Evotec’s PanOmics and PanHunter platforms along with AI-based drug discovery capabilities.

Original Article

Continue reading on STREETINSIDER.COM

Related Articles